216 related articles for article (PubMed ID: 16805951)
1. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model.
Griffin BT; O'Driscoll CM
J Pharm Pharmacol; 2006 Jul; 58(7):917-25. PubMed ID: 16805951
[TBL] [Abstract][Full Text] [Related]
2. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.
Griffin BT; O'Driscoll CM
Pharm Res; 2008 May; 25(5):1125-33. PubMed ID: 17975709
[TBL] [Abstract][Full Text] [Related]
3. Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.
Hosny KM; Hassan AH
Int J Pharm; 2014 Nov; 475(1-2):191-7. PubMed ID: 25178831
[TBL] [Abstract][Full Text] [Related]
4. Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies.
Lawless E; Griffin BT; O'Mahony A; O'Driscoll CM
Pharm Res; 2015 May; 32(5):1817-29. PubMed ID: 25428258
[TBL] [Abstract][Full Text] [Related]
5. Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system.
Hu M; Zhang J; Ding R; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2017 Apr; 43(4):687-697. PubMed ID: 28032534
[TBL] [Abstract][Full Text] [Related]
6. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid.
Bittner B; Guenzi A; Fullhardt P; Zuercher G; González RC; Mountfield RJ
Arzneimittelforschung; 2002; 52(9):684-8. PubMed ID: 12404883
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
[TBL] [Abstract][Full Text] [Related]
8. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems.
Wu H; Zhou A; Lu C; Wang L
Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Porter CJ; Charman SA; Charman WN
J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
11. Lymphatic transport of puerarin occurs after oral administration of different lipid-based formulations to unconscious lymph duct-cannulated rats.
Zhou A; Lu T; Wang L; Lu C; Wang L; Wan M; Wu H
Pharm Dev Technol; 2014 Sep; 19(6):743-7. PubMed ID: 23978005
[TBL] [Abstract][Full Text] [Related]
12. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol.
Caliph SM; Faassen FW; Porter CJ
J Pharm Pharmacol; 2014 Oct; 66(10):1377-87. PubMed ID: 24821499
[TBL] [Abstract][Full Text] [Related]
13. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Vyas TK; Shahiwala A; Amiji MM
Int J Pharm; 2008 Jan; 347(1-2):93-101. PubMed ID: 17651927
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
Jain R; Duvvuri S; Kansara V; Mandava NK; Mitra AK
Int J Pharm; 2007 May; 336(2):233-40. PubMed ID: 17207946
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic transport of orally administered probucol-loaded mPEG-DSPE micelles.
Han L; Yang Q; Shen T; Qing J; Wang J
Drug Deliv; 2016 Jul; 23(6):1955-61. PubMed ID: 25816053
[TBL] [Abstract][Full Text] [Related]
17. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport.
Trevaskis NL; Porter CJ; Charman WN
J Pharmacol Exp Ther; 2006 Feb; 316(2):881-91. PubMed ID: 16249368
[TBL] [Abstract][Full Text] [Related]
18. Stable phosphatidylcholine-bile salt mixed micelles enhance oral absorption of paclitaxel: preparation and mechanism in rats.
Zhao Y; Cui Y; Li Y; Li L
J Drug Target; 2014 Dec; 22(10):901-12. PubMed ID: 25077358
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
Martin-Facklam M; Burhenne J; Ding R; Fricker R; Mikus G; Walter-Sack I; Haefeli WE
Br J Clin Pharmacol; 2002 Jun; 53(6):576-81. PubMed ID: 12047481
[TBL] [Abstract][Full Text] [Related]
20. Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol.
Feng W; Qin C; Chu Y; Berton M; Lee JB; Zgair A; Bettonte S; Stocks MJ; Constantinescu CS; Barrett DA; Fischer PM; Gershkovich P
Eur J Pharm Biopharm; 2021 May; 162():43-49. PubMed ID: 33677067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
